Alpha Tau Medical Ltd

NASDAQ DRTS

Download Data

Alpha Tau Medical Ltd Gross Profit to Tangible Assets Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending September 20, 2024

Alpha Tau Medical Ltd Gross Profit to Tangible Assets Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The Gross Profit to Tangible Assets Ratio measures the gross profit generated per dollar of tangible assets (total assets minus intangible assets). It provides insight into the company's ability to generate gross profit from its tangible assets. A higher ratio suggests better efficiency in utilizing tangible assets to generate gross profit. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO Mr. Uzi Sofer
IPO Date March 8, 2021
Location Israel
Headquarters 5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees 121
Sector Healthcare
Industry Biotechnology
Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Similar companies

TNYA

Tenaya Therapeutics Inc

NA

NA

MNOV

MediciNova Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email